Y
Yi-Hui Peng
Researcher at National Health Research Institutes
Publications - 12
Citations - 576
Yi-Hui Peng is an academic researcher from National Health Research Institutes. The author has contributed to research in topics: Virtual screening & Docking (molecular). The author has an hindex of 9, co-authored 12 publications receiving 507 citations.
Papers
More filters
Journal ArticleDOI
Structure-Based Drug Design and Structural Biology Study of Novel Nonpeptide Inhibitors of Severe Acute Respiratory Syndrome Coronavirus Main Protease
I-Lin Lu,Neeraj Mahindroo,Po-Huang Liang,Yi-Hui Peng,Chih-Jung Kuo,Keng-Chang Tsai,Hsing Pang Hsieh,Yu-Sheng Chao,Su-Ying Wu +8 more
TL;DR: Interestingly, the most potent inhibitor induces protein conformational changes, and the inhibition mechanisms, particularly the disruption of catalytic dyad (His41 and Cys145), are elaborated.
Journal ArticleDOI
Important Hydrogen Bond Networks in Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Design Revealed by Crystal Structures of Imidazoleisoindole Derivatives with IDO1
Yi-Hui Peng,Shau-Hua Ueng,Chen-Tso Tseng,Ming-Shiu Hung,Jen-Shin Song,Jian-Sung Wu,Fang-Yu Liao,Yu-Shiou Fan,Mine-Hsine Wu,Wen-Chi Hsiao,Ching-Cheng Hsueh,Shu Yu Lin,Chia-Yi Cheng,Chih-Hsiang Tu,Lung-Chun Lee,Ming-Fu Cheng,Kak-Shan Shia,Chuan Shih,Su-Ying Wu +18 more
TL;DR: This study presents the structure of IDO1 in complex with 24, a NLG919 analogue with potent activity and demonstrates that extensive hydrophobic interactions and the unique hydrogen bonding network contribute to the great potency of imidazoleisoindole derivatives.
Journal ArticleDOI
Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities.
I-Lin Lu,Chien-Fu Huang,Yi-Hui Peng,Ying-Ting Lin,Hsing Pang Hsieh,Chiung-Tong Chen,Tzu-Wen Lien,Hwei Jen Lee,Neeraj Mahindroo,Ekambaranellore Prakash,Andrew Yueh,Hsin-Yi Chen,Chandra M. V. Goparaju,Xin Chen,Chun-Chen Liao,Yu-Sheng Chao,John T.A. Hsu,Su-Ying Wu +17 more
TL;DR: A successful example of employing structure-based virtual screening, a method that combines shape-based database search with a docking study and analogue search, to discover a novel family of PPARgamma agonists based upon pyrazol-5-ylbenzenesulfonamide.
Journal ArticleDOI
Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.
Mohane Selvaraj Coumar,Chang-Ying Chu,Cheng-Wei Lin,Cheng-Wei Lin,Hui Yi Shiao,Yun-Lung Ho,Randheer Reddy,Wen-Hsing Lin,Chun-Hwa Chen,Yi-Hui Peng,Jiun-Shyang Leou,Tzu-Wen Lien,Chin-Ting Huang,Ming-Yu Fang,Szu-Huei Wu,Jian-Sung Wu,Santhosh Kumar Chittimalla,Jen-Shin Song,John T.A. Hsu,John T.A. Hsu,Su-Ying Wu,Chun-Chen Liao,Chun-Chen Liao,Yu-Sheng Chao,Hsing Pang Hsieh +24 more
TL;DR: A focused library of furanopyrimidine was rapidly synthesized in parallel reactors and in situ screened for Aurora and epidermal growth factor receptor (EGFR) kinase activity, leading to the identification of some interesting hits.
Journal ArticleDOI
Identification of Substituted Naphthotriazolediones as Novel Tryptophan 2,3-Dioxygenase (TDO) Inhibitors through Structure-Based Virtual Screening
Jian-Sung Wu,Shu Yu Lin,Fang-Yu Liao,Wen-Chi Hsiao,Lung-Chun Lee,Yi-Hui Peng,Chia-Ling Hsieh,Mine-Hsine Wu,Jen-Shin Song,Andrew Yueh,Chun-Hwa Chen,Shiu Hwa Yeh,Chia-Yeh Liu,Shu-Yi Lin,Teng-Kuang Yeh,John T.A. Hsu,Chuan Shih,Shau-Hua Ueng,Ming-Shiu Hung,Su-Ying Wu +19 more
TL;DR: A structure-based virtual screening strategy, comprising homology modeling, ligand-support binding site optimization, virtual screening, and structure clustering analysis, was developed and used to identify novel tryptophan 2,3-dioxygenase (TDO) inhibitors.